Cancer
Malignant Colon Neoplasm
CI-CAN-00007995Explore in graph →
Top-level225 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007995Explore in graph →
Clinical trials
1,196 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (139)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT07127874 | A Study of PHN-012 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Pheon TherapeuticsINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT00034216 | Collection of Blood From Patients With Cancer | recruiting | — | 1,750 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02595957 | Genomic Services Research Program | recruiting | — | 5,000 | National Human Genome Research Institute (NHGRI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT03516942 | Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment | active not recruiting | — | 565 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840677 | Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer(TRIUNITE-08) | recruiting | Phase 2 | 70 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841236 | ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer | recruiting | Phase 2 | 23 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07834385 | Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis(NTLC75-ITA) | not yet recruiting | — | 40 | University Hospital of SplitOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07825766 | The Role of Total Abdominal Autonomic Nerve Preservation During the Resection of Right/Left Colon Cancer: Prospective Clinical Trial | active not recruiting | — | 200 | Fudan UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05677048 | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | active not recruiting | N/A | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02381561 | Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06263088 | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | recruiting | N/A | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03151564 | Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques | active not recruiting | N/A | 146 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05197322 | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer(NEOPRISM-CRC) | active not recruiting | Phase 2 | 88 | University College, LondonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07098182 | Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique) | recruiting | N/A | 50 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04739696 | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.(eCare) | active not recruiting | N/A | 538 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06202183 | Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial | recruiting | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04674267 | Resilience and Equity in Aging, Cancer, and Health (REACH)(REACH) | recruiting | N/A | 147 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | active not recruiting | Phase 3 | 400 | Massachusetts General HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07805369 | A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer | not yet recruiting | Phase 1 | 60 | DEM BioPharma, Inc.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | not yet recruiting | Phase 2 | 100 | Solstice Oncology, Inc.INDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps(FORTE) | recruiting | N/A | 9,500 | NRG OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06904365 | Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women(OvAR-Y) | recruiting | — | 11 | Washington University School of MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07143487 | Family Communications After Genetic Testing | recruiting | N/A | 4,186 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | recruiting | N/A | 420 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT07795528 | Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma(ADX-DRIVER-CRC) | recruiting | — | 392 | Ruijin HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05627635 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05652348 | Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer(Hi-STEP1) | recruiting | — | 48 | Technische Universität DresdenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07224022 | Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer(NACho) | not yet recruiting | Phase 2 | 24 | John Strickler, M.D.OTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07321106 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer | recruiting | Phase 1 | 80 | Cartography BiosciencesINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07669519 | Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy(NuvastaticTM) | recruiting | Phase 3 | 180 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | recruiting | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781774 | Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach | not yet recruiting | N/A | 200 | Washington University School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04780477 | Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer | active not recruiting | N/A | 60 | Emory UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06287814 | French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) | recruiting | — | 70 | University Hospital, MontpellierOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04364373 | D2 vs D3 Lymph Node Dissection for Left Colon Cancer(DILEMMA) | recruiting | N/A | 1,381 | Russian Society of Colorectal SurgeonsOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05722327 | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | active not recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05534087 | Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)(CLAUDIA) | recruiting | Phase 3 | 236 | Seoul National University HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials